Choksi Laboratories Ltd Falls to 52-Week Low Amidst Continued Downtrend

Stock Price Movement and Market Context

On 4 Mar 2026, Choksi Laboratories Ltd opened with a gap down of -5.13%, continuing a two-day losing streak that has resulted in a cumulative return decline of -20.32%. The stock’s intraday volatility was notably high at 11.86%, with the price touching an intraday low of Rs.81.85, representing a near 20% drop from previous levels. This performance starkly contrasts with the broader Healthcare Services sector, which fell by a more modest -3.42% on the same day.

Despite a recovery in the Sensex, which rebounded by 240.06 points after an initial sharp drop, Choksi Laboratories Ltd underperformed significantly. The Sensex currently trades at 78,768.88, down -1.83% for the day, while the stock’s day change was a steep -14.13%. The stock’s underperformance is further emphasised by its trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained downward momentum.

Long-Term Performance and Valuation Metrics

Over the past year, Choksi Laboratories Ltd has delivered a negative return of -26.11%, a stark contrast to the Sensex’s positive 7.87% gain and the BSE500’s 11.43% return. The stock’s 52-week high was Rs.236.70, underscoring the magnitude of the recent decline. This prolonged underperformance is reflected in the company’s Mojo Score of 26.0 and a Mojo Grade of Strong Sell, which was downgraded from Sell on 17 Feb 2026.

Financially, the company exhibits weak long-term fundamentals. Its average Return on Capital Employed (ROCE) stands at 7.91%, indicating limited efficiency in generating returns from capital investments. Net sales have grown at a modest annual rate of 12.43% over the last five years, which is relatively subdued for the sector. Additionally, the company’s debt servicing capacity is constrained, with a high Debt to EBITDA ratio of 3.61 times, signalling elevated leverage risks.

Recent Financial Results and Profitability

The company reported flat results for the quarter ended December 2025, with Profit Before Tax Less Other Income (PBT LESS OI) at a marginal loss of Rs. -0.01 crore, indicating minimal profitability. Despite this, profits have risen by 23.3% over the past year, a positive sign amid the broader decline in share price. The Price/Earnings to Growth (PEG) ratio stands at 1.9, suggesting that the stock’s valuation is somewhat aligned with its earnings growth, albeit at a discount compared to peers.

Choksi Laboratories Ltd’s valuation metrics include a very attractive Enterprise Value to Capital Employed ratio of 1.9, reflecting a discounted market valuation relative to its capital base. This valuation discount is notable given the company’s challenges but also highlights the market’s cautious stance.

Shareholding and Sector Comparison

The majority of the company’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. Within the Hospital & Healthcare Services sector, the stock’s performance has lagged behind, with the sector itself declining by -3.42% on the day. This sector underperformance, combined with the stock’s steep decline, underscores the specific pressures facing Choksi Laboratories Ltd.

Technical Indicators and Market Sentiment

Technically, the stock’s position below all major moving averages signals a bearish trend. The 5-day, 20-day, 50-day, 100-day, and 200-day moving averages all lie above the current price, indicating sustained selling pressure. The high intraday volatility of 11.86% further reflects uncertainty and active trading around the stock’s price levels.

In contrast, the broader market indices show mixed signals. The Sensex, despite opening sharply lower by 1,710.03 points, managed a partial recovery, though it remains below its 50-day moving average. The 50DMA itself is positioned above the 200DMA, suggesting a longer-term positive trend for the index. Meanwhile, the NIFTY PSU index reached a new 52-week high, highlighting sectoral divergences within the market.

Summary of Key Metrics

Choksi Laboratories Ltd’s current market capitalisation is graded 4 on the Mojo scale, reflecting its size and liquidity profile. The company’s Mojo Score of 26.0 and Strong Sell grade indicate significant caution based on fundamental and technical factors. The stock’s 52-week low of Rs.81.85 represents a substantial decline from its peak of Rs.236.70, underscoring the challenges faced over the past year.

While the company’s profit growth and valuation ratios suggest some underlying value, the combination of high leverage, subdued sales growth, and persistent price weakness has weighed heavily on the stock’s performance.

Conclusion

Choksi Laboratories Ltd’s fall to a new 52-week low of Rs.81.85 reflects a confluence of factors including weak long-term fundamentals, elevated debt levels, and sustained market pressure. The stock’s underperformance relative to both the broader market and its sector peers highlights the challenges it faces in regaining investor confidence. Trading below all major moving averages and exhibiting high volatility, the stock remains under close scrutiny as it navigates this difficult phase.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today